All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IkT-148009
Therapeutic Area: Neurology Product Name: IkT-148009
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 03, 2020
Details:
Inhibikase Therapeutics has filed two INDs for IkT-148009, one for PD and one for the treatment of PD-related gastrointestinal complications, and it expects to commence the first dosing of PD patients shortly after the conclusion of the offering.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AMT-143
Therapeutic Area: Neurology Product Name: AMT-143
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
AmacaThera has received approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ANK-700
Therapeutic Area: Neurology Product Name: ANK-700
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PrabotulinumtoxinA
Therapeutic Area: Neurology Product Name: ABP-450
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Daewoong Pharmaceutical
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Investment September 03, 2020
Details:
The milestone is expected to provide funding AEON's clinical programs into 2021. The U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ABP-450 to treat cervical dystonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PN-1007
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
In a dose titration study in mice, intravenous administration of PN-1007 was able to efficiently remove all anti-MAG IgM antibodies, strongly supporting the anticipated effective dose range for the upcoming phase I/IIa study in patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Linoleic Acid
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
Retrotope filed this IND for a PSP Phase 2/3 trial after 3 patients treated with RT001 in PSP Expanded Access protocols showed encouraging results after more than a year on drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NTX-001
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
Neuraptive will conduct a Phase 2 study evaluating the safety and efficacy of NTX-001 vs standard of care in patients with acute single transected peripheral nerve injuries of the upper extremities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sodium oligomannate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RLS-0071
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Children’s Research Holdings
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 21, 2020
Details:
Proceeds will fund advancement of programs addressing acute lung injury due to COVID-19 and severe birth asphyxia (HIE).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PLX-200
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2020
Details:
Company has received an IND approval from the U.S.FDA to study PLX-200 treatment on Juvenile Neuronal Ceroid Lipofuscinosis (JNCL or CLN3) patients.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
